• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Evolent Health Inc

    6/10/25 5:21:58 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary
    Get the next $EVH alert in real time by email
    S-8 1 d946530ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 10, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Evolent Health, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware  

    1812 North Moore Street, Suite 1705

    Arlington, VA 22209

      32-0454912

    (State or other jurisdiction of

    incorporation or organization)

     

    (Address of principal executive

    offices, including zip code)

     

    (I.R.S. Employer

    Identification No.)

    Evolent Health, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan

    (Full title of the plan)

    Jonathan Weinberg, Esq.

    General Counsel

    Evolent Health, Inc.

    1812 North Moore Street, Suite 1705

    Arlington, VA 22209

    (571) 389-6000

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copy to:

    Elizabeth A. Morgan, Esq.

    King & Spalding LLP

    1185 Avenue of the Americas, 34th Floor

    New York, NY 10036

    (212) 556-2100

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY STATEMENT

    This Registration Statement is filed by Evolent Health, Inc. (the “Company”) pursuant to General Instruction E to Form S-8. The contents of the Registration Statements on Form S-8 previously filed on June  8, 2015 (File No. 333-204785), June 18, 2018 (File No. 333-225714), June 15, 2021 (File No. 333-257118) and November 3, 2023 (File No. 333-275287) are incorporated by reference herein and made a part hereof, except as supplemented, amended or superseded by the information set forth below. This Registration Statement on Form S-8 is filed by Evolent Health, Inc. to register an additional 7,126,000 shares of Class A common stock that may become issuable under the Evolent Health, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan, as amended (the “Amended 2015 Plan”). The Amended 2015 Plan has been amended to (i) authorize an additional 7,126,000 shares of Class A common stock for issuance under the Amended 2015 Plan and (ii) authorize an additional 7,126,000 shares of Class A common stock that may be delivered pursuant to incentive stock options granted under the Amended 2015 Plan.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

     

    Exhibit

    Number

      

    Document Description

      5.1    Opinion of King & Spalding LLP with respect to the shares being registered.
     23.1    Consent of Deloitte & Touche LLP.
     24.1    Power of Attorney (included on the signature page hereto).
     99.1    Amendment to the Evolent Health Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan, filed as Appendix B to the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 25, 2025, and incorporated herein by reference.
    107    Calculation of Filing Fee Table.

     

    1


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Arlington, State of Virginia, on June 10, 2025.

     

    EVOLENT HEALTH, INC.
    By:   /s/ Seth Blackley
      Seth Blackley
      Chief Executive Officer

    POWER OF ATTORNEY

    Each person whose signature appears below hereby constitutes and appoints John Johnson and Jonathan Weinberg and each of them singly, his or her true and lawful attorney-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated and on the 10th day of June 2025.

     

    Signature

      

    Title

     

    Date

    /s/ Seth Blackley

    Seth Blackley

      

    Chief Executive Officer and Director
    (Principal Executive Officer)

      June 10, 2025

    /s/ John Johnson

    John Johnson

      

    Chief Financial Officer

    (Principal Financial Officer)

      June 10, 2025

    /s/ Aammaad Shams

    Aammaad Shams

      

    Chief Accounting Officer and Controller

    (Principal Accounting Officer)

      June 10, 2025

    /s/ Toyin Ajayi, MD

    Toyin Ajayi, MD

      

    Director

      June 10, 2025

    /s/ Craig Barbarosh

    Craig Barbarosh

      

    Director

      June 10, 2025

    /s/ Russell Glass

    Russell Glass

      

    Director

      June 10, 2025

    /s/ Peter Grua

    Peter Grua

      

    Director

      June 10, 2025

    /s/ Shawn Guertin

    Shawn Guertin

      

    Director

      June 10, 2025

    /s/ Richard Jelinek

    Richard Jelinek

      

    Director

      June 10, 2025

    /s/ Kim Keck

    Kim Keck

      

    Director

      June 10, 2025

     

    2


    /s/ Cheryl Scott

    Cheryl Scott

      

    Director

      June 10, 2025

    /s/ Brendan Springstubb

    Brendan Springstubb

      

    Director

      June 10, 2025

     

    3

    Get the next $EVH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVH

    DatePrice TargetRatingAnalyst
    11/13/2025$7.00Equal-Weight → Overweight
    Stephens
    11/13/2025$7.00Outperform
    BMO Capital Markets
    1/10/2025$15.00Buy
    Needham
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    4/22/2024$40.00Buy
    Citigroup
    More analyst ratings

    $EVH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evolent Health upgraded by Stephens with a new price target

    Stephens upgraded Evolent Health from Equal-Weight to Overweight and set a new price target of $7.00

    11/13/25 9:38:39 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    BMO Capital Markets initiated coverage on Evolent Health with a new price target

    BMO Capital Markets initiated coverage of Evolent Health with a rating of Outperform and set a new price target of $7.00

    11/13/25 9:13:18 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Needham initiated coverage on Evolent Health with a new price target

    Needham initiated coverage of Evolent Health with a rating of Buy and set a new price target of $15.00

    1/10/25 7:49:47 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden

    WASHINGTON, Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, and American Oncology Network (AON), one of the nation's fastest-growing community oncology networks, today announced a new model enabling high-quality, more affordable, and connected cancer care — all without relying on prior authorization. The national partnership seeks to improve clinical decision-making by introducing quality-focused interventions, driving clinical insights through an innovative data and analytics platform, and rewarding providers for high-quality care. As providers demonstrate adherence to quality, they will

    11/6/25 4:12:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Announces Third Quarter 2025 Results

    Q3 2025 financial results ahead of expectations.Announces more than $500 million in newly-contracted annualized revenue to launch in 2026.Expands leadership team to support accelerating growth.WASHINGTON, Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "We are happy to deliver a strong quarter, in the top half of our guidance for both Ad

    11/6/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025

    Company to Participate in Upcoming Conferences WASHINGTON, Oct. 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

    10/9/25 8:30:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Springstubb Brendan B bought $38,199 worth of shares (10,000 units at $3.82), increasing direct ownership by 20% to 58,821 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    11/19/25 4:23:02 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:20:54 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:18:12 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    SEC Filings

    View All

    Evolent Health Inc filed SEC Form 8-K: Other Events

    8-K - Evolent Health, Inc. (0001628908) (Filer)

    12/8/25 8:00:06 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Health Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Evolent Health, Inc. (0001628908) (Filer)

    12/2/25 7:32:53 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/14/25 3:37:07 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Smith Jill D. claimed no ownership of stock in the company (SEC Form 3)

    3 - Evolent Health, Inc. (0001628908) (Issuer)

    12/12/25 4:11:26 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Director Springstubb Brendan B bought $38,199 worth of shares (10,000 units at $3.82), increasing direct ownership by 20% to 58,821 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    11/19/25 4:23:02 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Chief Accounting Officer Shams Aammaad covered exercise/tax liability with 2,567 shares, decreasing direct ownership by 3% to 72,899 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    8/5/25 4:11:35 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Financials

    Live finance-specific insights

    View All

    Evolent Announces Third Quarter 2025 Results

    Q3 2025 financial results ahead of expectations.Announces more than $500 million in newly-contracted annualized revenue to launch in 2026.Expands leadership team to support accelerating growth.WASHINGTON, Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "We are happy to deliver a strong quarter, in the top half of our guidance for both Ad

    11/6/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025

    Company to Participate in Upcoming Conferences WASHINGTON, Oct. 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

    10/9/25 8:30:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners

    Transaction enhances focus on specialty condition management and accelerates Evolent's deleveraging path.Proceeds from the transaction to be used to prepay senior term debt; Immediately accretive to Evolent's free cash flow by more than $7 million per year.Evolent reiterates outlook for Q3 2025 and full year 2025 for Revenue and Adjusted EBITDA, excluding the effect of the transaction.WASHINGTON, Sept. 23, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced that it has agreed to sell its value-based primary care business, Evolent Care Partners ("ECP"), to Privia Health Grou

    9/23/25 4:10:00 PM ET
    $EVH
    $PRVA
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    $EVH
    Leadership Updates

    Live Leadership Updates

    View All

    Privia Health Expands Value-Based Care Footprint with Acquisition of Accountable Care Organization Business from Evolent Health

    ARLINGTON, Va., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced that it signed a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE:EVH). The ACO business cares for over 120,000 attributed lives through the Medicare Shared Savings Program (MSSP), as well as various commercial and Medicare Advantage programs. With this transaction, Privia Health will now serve approximately 1.5 million attributed lives in value-based care (VBC) arrangements across commercial, Medicare, Medicare Advantage and Medicaid. Privia Health will pay $100 million in cash at closing and up to an additional $13 million su

    9/23/25 4:10:00 PM ET
    $EVH
    $PRVA
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

    Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

    3/18/25 4:47:00 PM ET
    $CMBM
    $DOMO
    $EVH
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Computer Software: Prepackaged Software
    Other Consumer Services

    Define Ventures Appoints Carolyn Magill as Venture Partner

    The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

    3/11/25 5:30:00 AM ET
    $EVH
    $HIMS
    $LVGO
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    $EVH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/12/24 9:55:15 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    8/7/24 7:47:40 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    7/10/24 10:10:34 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary